United Orthopedic Corporation is an international designer, manufacturer, and distributor of orthopedic implant solutions. Founded in 1993, the company utilizes a vertically integrated manufacturing model to control design, development, and production processes. Its product portfolio includes total hip and knee replacement implants for both primary and revision surgeries, along with associated surgical instruments. The company serves orthopedic surgeons and healthcare institutions globally, providing clinical education and customer support alongside its medical devices.
More
Summarised from the company's own disclosures, fiscal year ended Oct 2026
Industry
Medical Devices
Homepage
unitedorthopedic.com
Sector
Healthcare
IR page
unitedorthopedic.com/investor-conference
Tags
orthopedic implants, hip replacement, knee replacement, surgical instruments, joint replacement, medical devices
More
Press page
—
Metrics
Market cap
NT$ 6.76B
Market cap (USD)
$ 205.186M
P/E
14.63
PEG
0.40
P/BV
1.69
P/S
1.11
P/OCF
9.42
P/FCF
—
Dividend yield
—
Turnover / mcap
—
ROE
14.1%
ROI
13.7%
ROIC
13.7%
Profit margin
9.9%
Revenue growing
Yes
Profits growing
Yes
Revenue up 3y
Yes
Revenue up 5y
Yes
Earnings growth 3y (net profit CAGR)
36.4%
Profitable
Yes
Margin expanding
No
Buying back stock
No
Diluting (TTM)
No
Debt/Equity
—
Podcast bulls (TTM)
Sign up
Podcast bears (TTM)
Sign up
Podcast sentiment (TTM)
Sign up
Podcast sentiment % (TTM)
Sign up
News sentiment (TTM)
0
Quality score
50.0%
Buys, 1w
Sign up
Buys, 1m
Sign up
Buys, 1y
Sign up
Sells, 1w
Sign up
Sells, 1m
Sign up
Sells, 1y
Sign up
Sign up to see this company's insider trades
Fundamentals
(all numbers in TWD)
Compare
All 28 figures
Annual
Quarterly
Compare with
×
Revenue
5.655B
4.653B
3.93B
3.169B
2.571B
2.342B
2.437B
2.332B
1.973B
1.383B
1.393B
1.101B
956.212M
859.581M
760.147M
728.329M
Net profit
562.497M
456.428M
384.201M
221.533M
52.271M
101.828M
88.584M
127.554M
130.264M
146.601M
133.807M
81.729M
21.344M
35.151M
57.96M
35.054M
Share price
112
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
P/S
1.91
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
Sign up to see institutional holdings
Sign Up
Podcast Mentions
Sign up to see podcast mentions and sentiment
Sign Up
Material information published on MOPS, newest first, subjects as filed in Chinese, guarantee and loan balance notices and routine equipment purchases included. The link opens the company's material information on MOPS.
AI comment
This is a routine notice announcing the date, time, and location of a scheduled investor presentation (earnings briefing). It does not contain any new financial data, guidance, or operational updates, and thus provides no information on company value.
AI comment
This is a correction notice regarding the filing of the third-quarter consolidated financial report. The headline explicitly states it is a 'correction' (更正) of a previously announced matter, and the text lists standard financial line items without revealing new substantive performance data or changes to the company's value proposition. Routine filings and corrections to previously published data are neutral.
AI comment
Routine regulatory filing regarding the extension of a revolving credit facility to a related party (United Orthopedic Corporation (France)). The amount is small relative to the parent's equity and cash flow, and such internal capital allocation is standard operational practice with no impact on shareholder value.
AI comment
This is a routine regulatory filing regarding the extension of a revolving credit facility to a 96%-owned subsidiary. The amount is small relative to the parent's equity and cash flow, and lending to a profitable subsidiary is standard capital allocation with no impact on shareholder value.
AI comment
The company's subsidiary is investing approximately EUR 6.5 million over five years to establish a sales and operations base in Italy to deepen market layout. This is a minor strategic expansion with a relatively small capital outlay, representing a modest positive step for growth.
AI comment
This is a routine regulatory filing announcing that the board has approved the Q3 2026 consolidated financial statements. While the text provides preliminary figures (revenue 4.59B TWD, net income 330.7M TWD for Jan-Sep), the event type is the formal approval/notification of the results release date/process, which is a standard procedural step. Without a direct comparison to prior year guidance or explicit mention of a surprise beat/miss in the headline or primary text structure, and given the '
AI comment
The board approved routine third-quarter consolidated financial statements, an academic partnership, the establishment of a sales office in Italy, and adjustments to fund lending. These are standard operational and administrative filings that do not convey material financial impact or new value drivers.
AI comment
The company appointed a new Chief Information Security Officer (CISO), replacing the previous CISO with the current head of the IT department. This is a routine management personnel change that does not impact the company's financial value or operations significantly.
AI comment
This is a routine regulatory filing notifying the market that Luxshare Precision (via its subsidiaries) has acquired a 33.55% stake in United Orthopedic, exceeding the one-third threshold. The transaction has already occurred, and this notice serves only as a formal disclosure of the completed shareholding change without announcing new terms, premiums, or strategic integration plans that would immediately alter the company's operational value or share price dynamics beyond the known deal.
AI comment
This is a routine administrative correction regarding the title of a newly appointed Information Department Director, which carries no financial or strategic implications for the company's value.
AI comment
The company appointed a new Chief Information Security Officer (CISO), replacing the former Vice General Manager with the current Head of Information. This is a routine management personnel change with no indication of distress or strategic impact on value.
AI comment
This is a routine filing correcting minor content in the previously published annual report. It does not reveal any new financial performance, strategic changes, or value-affecting information, making it neutral for investors.
AI comment
This is a routine filing announcing that the board of directors has approved the Q2 consolidated financial report. It does not contain the actual financial results or performance data, serving only as a procedural notice.
AI comment
This is a routine board resolution filing covering the approval of quarterly financials, dividend distributions, sustainability reports, and internal administrative appointments. These are standard corporate governance formalities that convey no new information regarding the company's value or future prospects.
AI comment
This is a routine notice announcing the date of the board meeting to review the Q2 financial report. It provides no financial data or strategic updates, only procedural information.
AI comment
This is a routine administrative notice regarding the temporary suspension of conversion rights for existing convertible bonds to facilitate dividend distribution. It does not convey new information about the company's value or performance.
AI comment
The company announced a cash dividend of approximately TWD 434 million, representing a payout of roughly 77% of FY2024 net income (TWD 456.4M). While routine, the high payout ratio and consistent distribution signal strong cash generation and shareholder-friendly capital allocation, warranting a minor bullish score.
AI comment
Routine regulatory filing regarding the lending of funds to a 96% owned subsidiary for business operations. The amount is small relative to the parent's equity and represents standard capital allocation with no new value implications.
AI comment
Routine board resolution reappointing members to the Sustainability Committee following the expiration of their terms; this is a standard governance formality with no impact on company value.
AI comment
Routine filing regarding the expiration of terms and reappointment of members to the Remuneration Committee. This is a standard corporate governance formality with no impact on company value.
Show all 20 news items
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat.
Shared by
Asian Century Stocks and
Uncovered Thai Stocks .
Thank you.
Base
Enforce Recency
Overview
Bull Bear
Competitive Advantages
Supply Chain
Segments
Earnings Results
Earnings Calls
Management
Stock Price Analysis
Comps
Forward Projection
Red Flags
Management Questions
Devils Advocate
Constraints
Share Value Compliance
Equity Research
United Orthopedic Corporation (ticker 4129.TWO), listed in Taiwan.
Copy
Clear
Copied
ETFs Holding United Orthopedic Corporation
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
AVEE
0.01%
6,000
$ 13.358K
Nov 16, 2026
DEXC
0.01%
8,000
$ 17.641K
Nov 12, 2026
DFEV
0.00%
42,000
$ 92.613K
Nov 12, 2026
DFEM
0.00%
122,000
$ 269.018K
Nov 12, 2026
DFSE
0.00%
7,000
$ 15.435K
Nov 12, 2026
DFAE
0.00%
77,000
$ 169.79K
Nov 12, 2026
DFAX
0.00%
50,924
$ 112.291K
Nov 12, 2026
AVEM
0.00%
21,000
$ 46.752K
Nov 16, 2026
AVES
0.00%
30,000
$ 66.788K
Nov 16, 2026
AVSE
0.00%
3,000
$ 6,678.82
Nov 16, 2026
AVXC
0.00%
4,000
$ 8,905.09
Nov 16, 2026